ReviewCancer treatment and research2025
Artificial Intelligence and Machine Learning Approaches in Designing Immunotherapy in Cancer.
Review in Cancer treatment and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) and machine learning (ML) are revolutionizing cancer immunotherapy by addressing the complex interplay between cancer and the immune system. This chapter explores how AI technologies enhance immunotherapy development across multiple domains: antibody design, response prediction, biomarker identification, and T-cell target discovery. In therapeutic antibody design, AI improves efficiency through predictive modeling of antibody-antigen interactions, structure prediction tools, generative models that create novel antibody sequences, and developability optimization. Clinical applications include AI-powered systems that predict immunotherapy responses using multi-omics data integration, helping distinguish pseudoprogression from true disease progression. Beyond conventional biomarkers like programmed cell death protein 1, AI enables identification of additional markers including tumor mutational burden, microsatellite instability, immune cell infiltration patterns, and novel genomic alterations. Multi-omics approaches leverage AI to synthesize diverse data types, uncovering complex biomarker signatures that more accurately predict treatment outcomes. For T-cell target identification, next-generation immunoediting platforms like Gritstone's EDGE™ system exemplify AI-powered approaches that precisely identify neoantigens by integrating sequencing technologies with sophisticated prediction algorithms (Table 2.1). These platforms support both personalized and shared antigen approaches to immunotherapy, potentially enhanced through integration with innate immune pathways. Despite remarkable progress, challenges persist in addressing tumor heterogeneity, immune evasion mechanisms, and technical limitations in prediction algorithms. The continued refinement of AI approaches, expansion to diverse cancer types, and integration with complementary therapeutic modalities represent promising future directions. Overall, AI and ML are poised to transform cancer immunotherapy by enabling more precise, effective, and personalized treatment approaches that harness the immune system's power against cancer.
Indexed as
Identifiers
40847227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.